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INTRODUCTION
The past 50 years have witnessed enormous progress in our under-
standing of cutaneous carcinogenesis. Model systems of carcinogen-
esis induced by ultraviolet light, chemical carcinogens, and tumor
viruses have been developed and studied. The results emphasize the
importance of the interplay between the inducing agent, host factors,
and other environmental factors in determining the likelihood of
developing malignant tumors. The study of xeroderma pigmentosum
has indicated how the inability to repair ultraviolet light induced DNA
damage can markedly accelerate the carinogenic effects of UV light.
The induction of cutaneous squamous cell carcinomas in mice by
chemical carcinogens has represented a system in which especially
important conceptual contributions have been made to our under-
standing of carcinogenesis in general. Such studies were among the
first to indicate that cells pass through various stages in the progression
to malignancy, which implies that several discrete changes may be
required to convert cells from normal to malignant. These observations
have provided an experimental framework in which to understand the
long latency periods seen in many forms of clinical cancer, where the
inducing agents usually remain unknown. Papillomaviruses represent
important agents of benign cutaneous tumors which have recently
been implicated in a variety of epithelial malignancies, especially
certain genital neoplasms.
In recent years, the focus of carcinogenesis studies has shifted to
mechanistic analyses and to the contribution of specific genes to
tumorigenesis. These analyses have suggested that cutaneous carino-
genesis at the molecular level results after several identifiable genetic
alterations have occurred in the cell. Thus model systems of cutaneous
carcinogenesis, in which early studies provided strong evidence for
cancer being a multistep process, are now identifying the specific
genes whose alterations contribute to malignant conversion. This
historically oriented review highlights these and related advances in
understanding cutaneous carcinogenesis and suggests some questions
that may be addressed in future studies.
ULTRAVIOLET CARCINOGENESIS
Knowledge concerning the role of environmental exposure to sunlight
in producing human skin cancer came more than a century after the
English surgeon, Sir Percival Pott, first postulated that chemicals in
soot were responsible for scrotal skin cancer in chimney sweeps [1]. In
the late 19th century, Paul Gerson Unna, a German dermatopathol-
ogist, used the term ‘‘seemanshaut’’ to describe changes in the skin of
sailors chronically exposed to solar radiation as a result of their
occupation [2]. Subsequently, Roffo in Argentina emphasized the
frequency with which malignant cutaneous neoplasms occur on
anatomic areas exposed to sunlight [3]. It is of interest that Roffo was
also convinced that the incidence of tumor induction could be directly
correlated with the cholesterol content of the involved skin area [3].
Black has proposed that reactive metabolites of cholesterol generated
by skin exposure to sunlight may initiate tumor formation [4].
Perhaps the first evidence that skin cancers could be induced in the
skin of experimental animals by chronic exposure to an artificial
source of ultraviolet radiation came from Findlay in 1928 [5]. The
techniques described by Findlay led the way to procedures employed
today for tumor induction that differ only slightly from those he
originally described.
While there was little argument about the carcinogenicity of
sunlight, the action spectrum of its oncogenic effect was debated until
the late 1950s when the meticulous studies of Blum and his associates
showed that the wavelengths responsible for skin cancer in mice were
primarily in the ultraviolet B (290–320nm) [6]. In these experiments
Blum defined threshold doses of radiant energy that were required to
elicit tumors, an upper limit of energy beyond which additional tumors
did not occur, and evidence that there was some degree of reciprocity
between the dose of delivered radiation and the latent period prior to
the development of visible tumors. The concept of reciprocity implies
that only the total dose of radiation administered determines whether a
photobiological event will occur. However, more recent studies
suggest that the carcinogenicity of UV radiation is greater when
administered fractionally [8].
Studies by Griffin were published in 1959 in a special issue of The
Journal of Investigative Dermatology that contained the proceedings of
a symposium held at Brook Lodge in Michigan devoted to studies
concerning the psoralens [9]. Griffin was interested in defining the
carcinogenicity of the psoralens, and his experimental design included
assessment of the interaction of ultraviolet C (UVC) and psoralens
administered orally to mice in the diet (0.5mg/kg of chow) or
intraperitoneally (0.4mg 1h prior to irradiation), as well as controls
with light and without drug and vice versa [9]. There was a tendency
for orally administered psoralen to protect against UVC-induced
cancer induction, whereas intraperitoneal administration evoked
tumors to a greater extent than did UVC alone (Fig 1). Similar findings
were obtained when broad spectrum UV radiation from a high-
pressure mercury arc was employed in the same type of protocol.
Additional studies were conducted with long-wave ultraviolet
radiation (UVA) which produced severe acute photosensitivity and the
largest incidence of tumors. Again, the orally administered psoralen
appeared to provide some degree of photoprotection, whereas the
parenterally administered compounds exacerbated the tumorigenic
response [10]. In that same issue of the Journal, Urbach compared the
carcinogenic effect of various photoactive agents in combination with
UVB radiation when administered topically, orally, or parenterally
[11]. The topical and parenteral administration of psoralens enhanced
the tumor induction response, whereas oral administration had little
effect (Fig 2).
These studies anticipated the concern about skin carcinogenicity in
patients treated with psoralen-ultraviolet A (PUVA) photochemo-
therapy for psoriasis and selected other diseases. In a prospective study
of 1367 patients, Stern et al found that patients with psoriasis have a risk
of systemic and cutaneous cancer no different than that in the overall
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population [12]. Furthermore, Stern et al also showed that patients with
psoriasis treated with PUVA have an incidence of cutaneous carcinoma
2.6 times that of the non-psoriatic population [13]. The risk increases to
3.7 in patients with a history of prior ionizing radiation, and to 10.2 in
patients with prior skin cancer. The expected ratio of basal cell to
squamous cell cancers (1:03) was reversed (1:1.5). In further studies,
Stern et al identified a dose-dependent risk of cutaneous squamous cell
carcinoma in PUVA-treated patients by showing a 12.8 fold higher risk
of tumor development with high-dose PUVA [14]. Studies from
European centers where PUVA photochemotherapy is also employed
have failed to confirm these findings which may relate to the
substantially lower doses of UVA light administered in these centers
[15]. Thus, both the cumulative UVA dosage and the regimen design
may influence the risk of skin cancer in patients treated with PUVA.
These data tend to confirm that the combination of orally administered
8-methoxypsoralen and UVA does enhance the risk of cutaneous
cancer in certain human populations. In a recent study published in the
Journal, Stern et al have followed these patients and found that in
subjects with more than 260 treatments there was an eleven-fold
increase in risk for skin cancer compared to patients receiving less than
160 treatments [16] (Table I).
The most-cited paper published in the Journal related to
carcinogenesis was that of Cleaver in which the role of defective
repair of structural DNA damage (pyrimidine dimers) in xeroderma
pigmentosum was explored [17]. A correlation between the absence of
DNA repair and symptoms of extreme UV sensitivity was observed in
human-skin fibroblasts cultured from patients with xeroderma
pigmentosum, an autosomal recessive disease characterized by
accelerated cutaneous malignancy. Thus, it was shown that defective
repair of UV-induced thymine dimers could be detected in UV
irradiated cells from such patients, but not from normal controls nor
from patients with different types of photosensitivity such as
Rothmund-Thomson syndrome, progeria, and the basal cell nevus
syndrome, among others. The extensive citation of this paper probably
relates to its detailed presentation of abnormal DNA repair in
xeroderma pigmentosum. Even more importantly, its careful explana-
tion of the process of excision repair of thymine dimers has made it an
extremely useful reference for teaching purposes (Fig 3).
In a subsequent paper, Cleaver described three new patients with
xeroderma pigmentosum in whom no abnormality of DNA excision
repair could be identified [18]. The importance of these observations
relates to their being the first description of the variant form of
xeroderma pigmentosum in which normal repair was identified The
data presented in this paper presaged the identification of multiple
complementation groups among patients with xeroderma pigmento-
sum [19,20]. In a recent review, Robbins has pointed out that at least
nine such complementation groups exist and that target cells in these
patients are hypermutable and hypertransformable [21].
During the past 50 years, considerable information has been
gathered regarding the relationship of solar radiation to non-
melanoma skin cancer in humans. With the advent of molecular
biology and the tools it offers for exploring the mechanism of disease
at the gene level, even greater advances will be possible in the years
ahead. For example, alterations in keratin gene expression are known
to occur in chemically induced skin cancers in mice [22]. In addition,
ultraviolet radiation can activate c-fos gene expression in cells [23].
These may prove to be useful markers for the transition between pre-
malignant change and frank tumor development. There is clearly a
need for additional information regarding oncogene expression in UV
carcinogenesis. Finally, the emergence of photoimmunology as a
major field within photobiology has been based in large measure upon
studies of the immunogenicity of UV-induced tumors in murine skin
[24]. UV radiation may stimulate T-suppressor cells that block the
host’s normal rejection of tumor cells, thereby permitting tumor
growth [25]. There is a need to unequivocally identify the
chromophore within the skin that initiates neoplastic response. Both
DNA and urocanic acid have been advocated, but further work is
needed to clarify this important issue.
New knowledge is needed concerning the relative carcinogenicity
the various components (UVA and UVB) of the solar spectrum the
contribution of exposure to artificial sources of light (for example, in
tanning equipment) to this process. The risk posed by the attenuation
Figure 1. Effect of 8-methoxypsoralen on the incidence of ear tumors in mice
exposed to ultraviolet light. Series I: U.V., 15min/day. Group 1A: Controls,
U.V. only. Group IB: 8-MP, 0.4mg/day, injected intraperitoneally. Group 1C:
8-MP in diet, 0.5mg/kg diet. (Reprinted from Griffin, J Invest Dermatol
32:367–372, 1959)
Figure 2. Incidence of ear tumors in Swiss mice treated with methoxsalen
(8MP) administered locally, intraperitoneally and orally. The difference in the
number of tumors present at the end of radiation is statistically significant
between the controls and the groups given methoxalen locally and
intraperitoneally, but not significant between the controls and the group given
the psoralen orally. (Reprinted from Urbach, J Invest Dermatol 32:373–378,
1959)
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of stratospheric ozone now seems indubitable, but it is crucial that this
be quantitated more precisely. Finally, there is a major need for more
innovative approaches to prevention of exposure. This may require
intensive educational efforts to inform the public about the use of
sunscreens and protective clothing, as well as the development of
more effective photoprotective agents.
CHEMICAL CARCINOGENESIS
The importance of environmental exposure in the development of
human cancer can be traced to the remarkably prescient observations
of Sir Percival Pott, a London surgeon, who, in 1775, first reported on
the unusual susceptibility of chimney sweeps exposed to soot for the
development of cutaneous cancers of the scrotum [1]. In 1823, Earle
Table I. Relative Risk and 95% Confidence Intervals (CI) of Squamous Cell Carcinoma Compared to Population
Expected Occurrences for Tumors That Developed at Least 58 Months After Initial Treatment by Number of PUVA
Treatments as of Follow-up Year Five
All patients with tumorsa First SCC at least 58 months after initial treatmentb
Treatments RR 95% CI RR 95% CI
4.2c (2.6–6.4)
160–199 25.5 (13.6–43.6) 22.2 (10.6–40.9)
200–259 37.5 (23.5–56.7) 32.1 (18.7–51.4)
260+ 62.5 (35.0–103.1) 50.1 (24.9–89.5)
All Doses 11.4 (9.1–14.2) 9.5 (7.2–12.3)
aIncludes all patients with squamous cell cancers that developed at least 58 months after initial treatment.
bIncludes only patients with a first post PUVA squamous cell cancer that developed at least 58 months after initial treatment.
cIncidence counted as persons with tumors.
(Reprinted from Stern et al., J Invest Dermatol 91:120–124, 1988)
Figure 3. Scheme for DNA repair in mammalian cells indicating the necessary stages of repair, but not every chemical reaction. Xeroderma pigmentosum
fibroblasts are defective in the enzymatic breakage step (i.e., are defective in an endonuclease enzyme). (Reprinted from Cleaver, J Invest Dermatol 54:181–195,
1970)
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reviewed some of the clinical features of these individuals and
wondered if there were constitutional predisposing factors that
enhanced their susceptibility to the carcinogenic effect of soot,
thereby raising the question whether genetic traits could influence
the risk of cancer formation in exposed individuals [26].
In the late 19th century, Butlin remarked that a curious kind of
experiment of nature had been occurring for at least 100 years in
which repeated application of a chemical substance or of a mixture of
chemical substances to a particular part of the integument, which is
not at all disposed to cancer, rendered it preeminently disposed to
cancer in some, but not all, individuals [27].
The use of experimental animals for the study of cutaneous cancer
was not reported until the second decade of the 20th century when
Japanese investigators showed that repetitive application of crude coal
tar to the ears of rabbits evoked skin neoplasms [28]. This was among
the first published studies to show that the skin of animals provided a
useful experimental model for cancer research.
In 1930, Kennaway and Hieger first showed that repetitive skin
application of 1,2,5,6-dibenzanthracene, a pure compound isolated
from coal tar, produced cutaneous tumors in experimental animals
[29]. Just three years later, in 1933, the polycyclic aromatic
hydrocarbon benzo[a]pyrene (BP) was isolated from crude coal tar.
This seminal observation led to extensive studies that confirmed the
carcinogenic properties of a variety of polyaromatic hydrocarbons
which are by-products when fossil fuels such as coal are incompletely
combusted.
One of the earliest papers describing cutaneous chemical
carcinogenesis from this class of agents was that of Cowdry published
in The Journal of Investigative Dermatology in 1945 [31]. Initially,
most investigators believed that repetitive topical application of
carcinogenic chemicals was the sole way to evoke tumors in the
skin, but Cramer and Stowell showed that such neoplasms could
develop following a single application of a polyaromatic hydrocarbon
[32]. This led to the observation that a single skin application of a
carcinogen followed by repetitive exposure to a non-carcinogenic
irritant such as croton oil could elicit tumors in the skin [33,34]. These
results showed that the chemical induction of cancer in the skin was
dependent upon two distinct phenomena: (1) an initial change evoked
by the carcinogen that is specific and irreversible and is known as
initiation; and (2) tumor promotion in initiated skin, a process
requiring repeated exposure to certain types of irritant chemicals
known as promoters whose effects are initially reversible, but with
repeated exposure, become irreversible.
Thus, by the 1950s, it was clear that chemical carcinogenesis in the
skin required two distinct categories of events, initiation and
promotion. Subsequently, a third stage known as progression or
conversion emerged to explain the observation that many of the
tumors that develop during initiation and promotion are benign
papillomas that regress spontaneously if tumor promotion ceases. With
continued application of tumor promoters, some of the benign
papillomas undergo malignant conversion or progression and form
squamous cell carcinomas.
Initiation The knowledge that tumor initiation was an irreversible
step led to the concept that this must be associated with some type of
genetic damage to cells. With the discovery of DNA as the heritable
matrix of the cell, chemical injury to this nucleic acid was suggested as
the critical event in tumor initiation. Thus evolved the somatic
mutation theory of chemical carcinogenesis which states that the
initiation of cancer requires the production of a structural change in
cellular DNA that is then transmitted to the progeny of the mutated
cell. Confirmation of this concept was published in 1964 when
Brookes and Lawley showed that a series of polycyclic hydrocarbons
applied to the skin were covalently bound to cutaneous DNA, and that
the extent of such binding could be correlated with their capacity to
produce tumors [35]. Binding of chemical carcinogens to skin
constituents and its role in tumor initiation was further confirmed
with the direct acting carcinogen B-propiolactone which was shown
to form covalent bonds with DNA [36]. The degree of DNA binding
was found to vary directly with the susceptibility of the strain of mouse
to cutaneous tumor induction.
The mechanism of tumor initiation by indirect acting chemical
carcinogens such as BP has been studied extensively over the last 45
years. In 1943, Weigert showed that the characteristic fluorescence of
BP was changed following its application to skin and suggested that
metabolites of the parent compound could account for its carcino-
genic effect [37]. A decade later, Norden used the term ‘‘metabolite
fluorescence’’ to describe the alteration in BP that occurred in skin
[38]. Interestingly, he showed that this occurred sequentially in hair
follicles, sebaceous glands, and epidermis. It was also stated that these
fluorescence changes developed more rapidly in the skin of animal
species with greater susceptibility to tumor induction.
These developing concepts were then confirmed by extensive
studies showing that cells contain a membrane-bound monooxygen-
ase system that functions to introduce molecular oxygen into a broad
range of substrates, thereby, altering their biological activity and
enhancing their excretion from the body. This enzyme system is
dependent upon the heme-protein cytochrome P-450 that encom-
passes a superfamily of at least 10 gene families of which eight are
known to exist in mammals [39,40]. These genes code for a limited
number of P-450 isozymes, perhaps 20–30, that metabolize an
enormously broad range of substrates including exogenous drugs,
carcinogenic chemicals, and endogenous steroid hormones and
various biologically active lipids such as arachidonic acid, prosta-
glandins, and leukotrienes. The isozyme distribution of P-450, in a cell
or a tissue influences susceptibility to the toxic effects of parent
compounds and/or their metabolites. This somewhat paradoxical
situation is due to the differential capacity of various P-450 isozymes
to generate metabolites with either diminished or enhanced biological
activity. As will be discussed, it is the P-450-dependent production of
highly reactive metabolites of PAHs such as BP and their subsequent
binding to cellular macromolecules that appears critical for the
initiation of cancer [41].
Knowledge that BP is metabolized in skin was greatly enhanced by
the observation of Wattenberg and his associates who pioneered a
histochemical fluorescence assay showing that BP underwent some
metabolic changes in cutaneous tissue [42]. This rather crude
analytical procedure was further refined and led to the development
of a highly sensitive enzyme assay known as aryl hydrocarbon
hydroxylase (AHH) that is still widely used to measure BP metabolism
[43]. Initially, it was believed that AHH activity was primarily a
detoxification reaction in which carcinogenic parent compounds such
as BP were converted into phenolic metabolites that had no
carcinogenic effect when applied to skin. Subsequently, it was shown
that AHH activity was inducible—that is, following exposure to certain
PAHs the detectable catalytic activity increased, and spectral
measurement of the induced microsomal P-450 revealed that a new
isozyme with a 2-nm shift in absorbance toward the blue. (P-448 or
P1-450) was present [44].
The induction response of P-450 to PAHs was shown to be
dependent upon several factors involving multiple gene products at
different loci [45]. Furthermore, induction required the presence of a
cytosolic receptor protein known as the Ah receptor that bound and
then translocated the inducer-receptor complex to the nucleus prior to
the expression of increased AHH activity [46]. This results in binding
of the ligand-receptor complex to specific regions flanking the 50-end
of the P-450 gene that culminates in enhanced rates of transcription of
its mRNA [47]. Recent studies have confirmed that the Ah receptor is
present in the human squamous cell carcinoma line A-431 [48]. This
124S Bickers and Lowy THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
finding has helped to confirm earlier evidence that such receptors are
present in the liver [49].
AHH induction occurs in cultured human epidermis [50] (Fig 4)
and this response in mammalian skin has been further characterized
using highly specific monoclonal antibodies directed against purified
isozymes of hepatic P-450. Topical application of the PAH 3-
methylcholanthrene to neonatal rodents results in induction of AHH
and other P-450-dependent enzymes within 12–24hours. Western blot
analysis of epidermal microsomes prepared from untreated animals
shows no reactivity with MAbs 1-7-1 or 2-66-3 which are directed
against PAH-inducible P-450c (P-450) and phenobarbital-inducible
P-450b (P-450), respectively [51], whereas epidermal microsomes
prepared from the carcinogen-treated animals showed distinct
immunoreactivity with MAb 1-7-1, and AHH activity was more than
70% inhibited by this antibody. Similar findings were obtained using
crude coal tar and, taken together, these results indicate that topical
application of PAHs either in pure form or as complex mixtures results
in the induction of specific P-450 isozymes in the epidermis [52].
The importance of enzyme induction by PAHs in the initiation of
cancer is based upon the metabolites generated by P-450-dependent
AHH in concert with epoxide hydrolase. BP is initially metabolized at
the 7,8-position resulting in the insertion of molecular oxygen yielding
the epoxide BP-7,8-oxide. This is a substrate for epoxide hydrolase
which cleaves the epoxide to produce BP-7,8-dihydrodiol. The
dihydrodiol is a substrate for P-450 and is converted to a specific
BP-diol-epoxide known as (þ )-7B, 8a-dihydroxy-9a,10a-epoxy
7,8,9,10 tetrahydrobenzo[a]pyrene (BPDE-I), a highly reactive species
that binds to cellular macromolecules including DNA. This P-450-
dependent metabolic activation process is thought to be critical for the
initiation of cancer by PAHs such as BP [53,54]. This metabolite is the
ultimate carcinogenic metabolite of BP and forms an adduct between
its C-10 position and the 2-amino group of the guanine residues in
DNA [55]. This binding results in a slight distortion of the DNA helix
(lying in the minor groove) and can also induce Z DNA conformation.
Initiation and Oncogenes in Chemical Carcinogenesis During
the 1980s, there has been a revolutionary change in prevailing
concepts concerning the mechanism of cancer induction. The
seemingly contradictory notion that humans carry nucleotide se-
quences in their genome, that code for components of signal
transduction pathways that are important in regulating normal growth
control and differentiation, has opened up an entire new chapter in
cancer research. Initiating carcinogens may act by mutating proto-
oncogenes, thereby activating these proto-oncogenes and converting
them to oncogenes, the expression of which results in abnormal
growth control and disordered differentiation [56]. Variations on this
general theme may characterize viral carcinogenesis evoked by
retroviruses which, in effect, provide naturally occurring vectors for
host-derived oncogenes [57]. Retroviruses are central to the argument
that implicates a cellular gene in oncogenesis. The progenitor of a
retroviral oncogene is also the target for mutation by a provirus
without an oncogene.
Carcinogenesis can therefore be conceptualized as a disturbance in
cellular processes that normally control the function/expression of
growth factors, their receptors, or pathways of signal transduction [58].
Since chemical carcinogens cannot introduce new DNA into the
genome, they must evoke a neoplastic response by coaxing a target
cell to manifest aberrant behavior by distorting that cell’s normal
ability to control its growth and differentiation. DNA transfection
experiments with NIH 3T3 fibroblasts showed that human tumors and
cells transformed by chemical mutagens contain oncogenes [59].
These oncogenes were found to be mutant versions of the Harvey ras
(Ha-ras) gene. Ras proteins coded by these genes have the function of
GTP binding and hydrolysis and are part of a family of proteins
(G proteins) which convey extracellular signals to adenylate cyclase.
Proto-oncogene activation can occur in several ways [58]: (1) re-
combinational transduction into retroviruses creating viral oncogenes
(this is unlikely in human cancer); (2) dosage effects: quantitative
mechanisms resulting from increased or deregulated expression of an
essentially normal gene product (examples of this mechanism include
chromosomal translocation, gene amplification and proviral insertion
and activation, hypomethylation of DNA and derepression or
transactivation); (3) qualitative mechanisms resulting from specific
somatic mutations in the coding sequence of the gene creating a gene
product with altered structure and biochemical properties. Ras
activation is a prototype of a qualitative mechanism of oncogene
activation. The Ras gene product p21 is a palmitoylated plasma
membrane anchored protein of 188 or 189 amino acid residues that
binds guanine nucleotides and has intrinsic GTPase activity. Mutated
ras genes result in mutated p21 products with lowered intrinsic
GTPase activity and/or hindered interaction with GTPase activating
protein.
A point mutation of the 12th codon of the rat Ha ras gene has been
verified in mammary carcinomas induced by the direct acting
carcinogen nitrosomethylurea [60]. Using a mouse-skin carcinogen-
esis model of initiation with dimethylbenz[a]anthracene (DMBA) and
promotion with the phorbol ester TPA, it has been shown that both
benign papillomas and squamous cell carcinomas contain an
activated Ha-ras oncogene that carries an adenine to thymine point
mutation at codon 61 [61]. Other PAHs can cause the same response
[62]. Ha-ras expression is an early event in skin carcinogenesis with
steady state levels of Ha-ras poly (A)þ RNA elevated 5–10 fold in
papillomas after seven weeks of promotion with TPA [63]. Further
studies showed that early-stage papillomas contain a point mutation in
the 61st codon of the Ha-ras gene as early as nine weeks after initiation
with DMBA, as detected by restriction nuclease digestion [64].
In summary, tumor initiation by PAHs in mammalian skin appears
to be the result of direct exposure of the tissue to the carcinogen,
transport of the carcinogen to a target cell (keratinocyte), binding to a
cytosolic Ah receptor, ligand-receptor transport to the nucleus, DNA-
binding of the ligand-receptor complex, enhanced transcription of
P-450c, metabolic activation of the carcinogen in the endoplasmic
reticulum with production of highly reactive diol-epoxides, covalent
DNA binding of the ultimate metabolite to a specific nitrogen in
Figure 4. Human epidermal AHH as a function of BP concentrations. Enzyme
activity was measured after 60min. The concentration of BP was varied as
indicated in the figure. A Lineweaver-Burk representation of the data for
determination of an approximate Km value is provided in the inset. (Reprinted
from Bickers et al., J Invest Dermatol 83:51–56, 1984)
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guanine residues, activation of the Ha-ras proto-oncogene by an A: T
base substitution at the 61st codon, synthesis of an aberrant protein
product (p 21) by the activated oncogene, and altered signal
transduction by abnormal regulatory control of G protein function
resulting in increased rates of cell proliferation and distorted
differentiation.
Tumor Promotion The two-stage concept of skin-tumor induction
requires initiation by a carcinogenic chemical, as described above,
followed by multiple exposure to compounds which have very weak
or no carcinogenic activity when tested alone, but markedly enhance
tumor yield when applied repeatedly. The classic tumor promoter
studied initially was croton oil, a skin irritant with little or no ability to
induce tumors. The phorbol esters are specific tumor promoting agents
that have been isolated from croton oil, and the prototype that has
been most widely studied is 12-0-tetradecanoyl phorbol-13-acetate
[65]. Features common to most tumor promoters include the capacity
to elicit skin irritation, inflammation, and hyperplasia [66]. TPA
exhibits a highly pleiotropic response including effects on DNA
synthesis (Fig 5), cell morphology, membrane transport, phospholipid
metabolism, protein phosphorylation, growth factor receptor binding,
cell proliferation and differentiation, chromosomal stability, induction
of expression of viral genes, enhancement of malignant transformation
by chemicals, viruses, and radiation and transient mimicry of the
transformed phenotype [67]. Exposure of cells to TPA induces mitogen
sensitive genes such as C-myc, C-fos, actin, ornithine decarboxylase
(ODC), proliferin, secreted lysosomal protein, and T-cell growth
factor.
Evidence that TPA binds to and activates protein kinase C (PKC) has
helped to link the fields of tumor promotion, growth factors, signal
transduction, and the action of specific oncogenes [67]. The PKC
enzyme has two domains: (1) a catalytic domain with ATP/protein
binding sites, and (2) a regulatory domain controlled by allosteric
factors such as lipid, Caþ þ , diacylglycerol (DAG), or lipid and TPA.
The regulatory domain also contains a peptide sequence that acts as a
pseudosubstrate inhibitor of the catalytic domain when the enzyme is
inactive. Experimental manipulation of cells such that they over-
express PKC activity evokes substantial alteration in the behavior of
the cells. The normal down regulation of TPA responses is abrogated;
e.g., shortened exponential doubling time of cells in monolayer
culture; growth of cells to high saturation density; formation of small,
dense foci at post-confluence and anchorage independent growth.
These findings amplify the concept that PKC plays a pivotal role in
normal cellular growth control and mediates several of the cellular
effects of the phorbol ester tumor promoters. Thus, disturbances in the
activation or down regulation of PKC may be critical in tumor
promotion and multistage carcinogenesis. Cells with overexpressed
PKC are much more susceptible to transformation by an activated
H-ras oncogene than are control cells, but whether they are also more
vulnerable to malignant transformation by chemical carcinogens
remains to be determined.
It should also be emphasized that tumor promoters appear capable
of inducing a point mutation in the 61st codon of the H-ras oncogene
in spontaneously initiated papillomas and carcinomas in the skin of
Sencar mice [68]. This may result in predisposition of cells containing
the mutation to powerful selection and amplification processes
stimulation by the promoters. An alternate interpretation would be
that the tumor promoter itself induces the mutation. Other studies have
shown that the presence of the point mutation in the 61st codon of the
Ha-ras oncongene in a spontaneously transformed epidermal cell line
produces papillomas on prepared epidermal graft beds in athymic
nude mice [69]. Furthermore, it has been demonstrated that increases in
the clonogenic population of keratinocytes harvested from adult murine
epidermis is a consequence of promotion rather than initiation [70].
The ability of TPA to affect gene regulation has been assessed by
developing a cDNA clone using polyadenylated RNA obtained from
C3H T 1012 cells four hours after treatment with TPA. A cDNA clone
has been isolated, the mRNA of which is induced up to 20-fold in
response to TPA, PDGF, EGF, and DAG or serum [67]. This has been
called phorbin (phorbol ester induced). Sequence analysis of the
phorbin cDNA (730 base pairs) preducts a cysteine-rich secreted
protein with a molecular weight of 22.6 kilodaltons. It shares sequence
homology with two similar substances known as erythroid potentiating
activity and tissue inhibitor metalloproteinase.
Tumor promoters such as TPA exert an influence on a number of
fundamental pathways. They induce the enzyme ornithine decarboxy-
lase (ODC) that catalyzes the initial step in the formation of
polyamines substances that are involved in cell proliferation. Studies
with a-difluoromethyl ornithine, an irreversible inhibitor of ODC,
have shown that it abrogates the tumor promoting effects of TPA [71].
The process of tumor promotion, unlike initiation, is a continuum
that requires a series of multiple discrete exposures of initiated cells
over time to exert a biologic effect. The explanation for this is
unknown, but tumor promotion has been divided into at least two
phases known as stage I (conversion) and stage II (propagation) [72]. A
marker of Stage I promotion in the skin is the induction of so-called
dark basal keratinocytes, whereas Stage II promoters can induce ODC,
stimulate DNA synthesis, and function as tumor promoters, but do not
induce dark basal keratinocytes. A prototype of Stage II promoters is
mezerein, a compound that is only marginally effective as a tumor
promoter when applied solely following initiation. In contrast,
mezerein is highly effective if begun four weeks after TPA. Another
stage II promoter is DAG, a second messenger generated by
phospholipase C that mimics TPA insofar as ODC induction, DNA
synthesis, and arachidonic acid release in epidermis is concerned [73].
Further confirmation of the existence of two stages of tumor promotion
have come from studies with inhibitors of each stage. Thus,
fluocinolone acetonide and tosyl phenylalanine chloromethyl ketone
Figure 5. Stimulation of DNA synthesis in mouse epidermal cell cultures after
exposure to TPA. Epidermal cells in culture for 24 h were exposed for 1 h or
continuously to various doses of TPA. At the times indicated after treatment,
the cells were pulsed for 1 h with 1 mCi/ml [3H]TdR, scraped, and frozen.
DNA specific activity was determined for each group and compared to the
solvent control. (Reprinted from Yuspa et al., J Invest Dermatol 67:199–208,
1976)
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block stage I tumor promotion, whereas retinoic acid is only effective
against stage II promotion. It is also important to emphasize that
inhibitors of phospholipase A2 and of lipoxygenase are also capable of
blocking TPA-induced tumor promotion [71]. Other agents capable of
tumor promotion of interest to dermatologists include anthralin and
benzoyl peroxide [74,75]. However, it should be emphasized that
benzoyl peroxide has only been shown to have tumor promotion
effects after chemical initiation, but not after initiation with ultraviolet
radiation [76].
Oxidant promoters can activate protein kinase C, but cannot bind
to it, and they can attack lipid-rich membranes and activate
phospholipase A2 resulting in the release of archidonic acid and the
subsequent synthesis of prostaglandins. Reactive oxygen species
including superoxide anion and hydrogen peroxide can stimulate
prostaglandin synthesis in aortic endothelial cells, and it is con-
ceivable that a similar effect occurs in epidermal cells [77]. Calcium
efflux from membrane stores may raise intracellular calcium
concentrations, thereby influencing tumor promotion.
Finally, it is known that cell-cell communication is fostered by gap
functions, and that TPA can block this phenomenon [78]. This may be
associated with an increase in protein kinase C activity, suggesting that
second messenger pathways are activated and may contribute to this
effect of TPA, the end result of which is blockade of normal inhibitory
signals by cell-cell contact with expansion of initiated cells into
proliferating clones.
In summary, tumor promotion requires multiple exposures to
agents that share the ability to promote skin inflammation, irritation,
and hyperplasia. A major effect of tumor promoters is the binding to
and acitvation of protein kinase C, leading to protein phosphorylation,
enhanced gene expression, clonal expansion of proliferating cells
culminating in benign papilloma, and/or carcinoma formation.
Progression This stage describes the conversion or progression of
benign papillomas into malignant squamous cell carcinomas. Thus,
clones of cells generated by initiation and promotion must undergo
additional change(s) to produce malignant neoplasms. It is thought
that initiated and promoted cells may have an unstable genome that
tenders them hypersensitive to further exposure to genotoxic insult and
leads to further aberrations in growth control that amplify the risk of
transition of malignancy [79]. Other factors that destabilize the
genome may include deranged repair of carcinogen-induced DNA
damage and activation of viral and cellular oncogenes.
TUMORIGENIC EFFECTS OF COMBINED ULTRAVIOLET
RADIATION AND CHEMICAL CARCINOGENS
While the independent carcinogenic effects of ultraviolet radiation
and of chemicals is beyond dispute, the result of combined exposures
to these agents remains somewhat controversial. Findlay first showed
that UV radiation and coal tar enhanced the risk of tumor development
[80], whereas others showed that the use of pure chemicals rather than
complex mixtures obviated this effect. Epgein and Epstein showed that
UV radiation combined with DMBA application to skin accelerated
tumor induction [81]. This was confirmed by Stenbach who showed
that irradiation 24 h prior to repeated applications of DMBA increased
tumor yield, whereas irradiation 1 h after carcinogen application
diminished tumor formation [82] (Fig 6). Similarly, pre-exposure to UV
radiation followed by a single application of benzo[a]pyrene followed
by repeated application of the promoting agent croton oil augmented
tumor development. All of these tumors were said to be benign
papillomas and squamous cell carcinomas. It was postulated that the
ability of UV radiation to enhance BP-induced cancer could relate to
enhanced binding of the carcinogenic chemical to DNA [83].
Recent studies indicate that prior exposure of mice to UV radiation
may exert profoundly different effects on chemical carcinogenesis,
depending upon the protocol employed. Thus, exposure of animals to
UVB alone five times weekly for 13 weeks, followed by repeated
application of benzo[a]pyrene, led to enhancement of tumor induc-
tion, whereas initiation-promotion with DMBA and TPA following a
similar UV radiation protocol produced far fewer tumors [84,85]. The
explanation for these conflicting results awaits further studies.
The mechanism of the additive efforts of UV radiation and crude
coal tar on cutaneous cancer induction in mice has been explored
[86]. UV radiation alone was shown to increase slightly the activity of
P-450-dependent enzymes crucial for the metabolic activation of poly
aromatic hydrocarbons, such as BP and DMBA. Pretreatment with
topically applied crude coal tar followed by UV light produced
additive and/or synergistic enhancing effects on the activity of these
Figure 6. Experiment A: Number of grossly observed tumors induced by 7,12-
dimethylbenz[a]anthracene (DMBA) and ultraviolet (UV) light. Group 1
received DMBA only; group 2, UV light only; group 3, UV light 24 h before
DMBA; group 4, UV light 1 h before DMBA; and group 5, UV light 1 h after
DMBA. (Reprinted from Stenback, J Invest Dermatol 64:253–257, 1975)
Figure 7. Effect of UVB and CCT, alone and combined, on generation of
specific metabolites of BP by cutaneous microsomal enzymes. (Reprinted
from Mukhtar et al., J Invest Dermatol 87:348–353, 1986)
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enzymes (Fig 7). It is possible that this enhancement of enzyme activity
that can activate carcinogens plays an important role in the augmented
development of skin cancer that occurs in animals and humans
exposed to this combination of carcinogenic agents.
Chemoprevention of Environmental Cancer Knowledge that
solar radiation and/or exposures to chemicals can elicit tumor
formation in the skin, and the gathering evidence indicating that a
variety of genetic and epigenetic phenomena are associated with this
type of biologic response has led to the concept that nontoxic
chemicals that interfere with these phenomena could offer a useful
strategy for diminishing cancer risk [87]. Studies with two such classes
of anticarcinogens have been conducted in murine skin. Naturally
occurring polyphenols such as ellagic acid and tannic acid, which
occur in substantial amounts in foodstuffs such as fruits, vegetables
and nuts, are potent inhibitors of the metabolic activation of chemical
carcinogens and have been shown to reduce the absolute numbers of
tumors and to prolong the latent period prior to tumor development
[89]. Similar results have been obtained with the imidazole antifungal
clotrimazole [90].
VIRAL CARCINOGENESIS
Papillomaviruses are the major group of viruses that induce cutaneous
tumors. The first serial transmission of papillomas with the cottontail-
rabbit papillomavirus (CRPV) was achieved by Richard Shope a few
years before the founding of the Society for Investigative Dermatology
[91]. Human papillomaviruses (HPV), the etiological agents of warts
whose transmissible nature had been demonstrated earlier (reviewed
in reference 92) were subsequently identified as being closely related
agents. Timely reports of virus particle morphology and analysis of
HPV lesions were published in the JID [93–95].
With CRPV (reviewed in reference 96), papillomas could be
induced serially in wild rabbits by inoculating their skin with cell-free
extracts from rabbit papillomas that had developed either sponta-
neously or via experimental inoculation. While the vast majority of the
papillomas eventually regressed spontaneously, some lesions persisted
and eventually progressed to malignant squamous cell carcinomas.
Experimental inoculation of domestic rabbits with CRPV also induced
papillomas, but with at least two important differences from those of
the wild rabbits: the lesions did not produce detectable amounts of
infectious virus (in contrast to experimental lesions in wild rabbits,
serial propagation could not be achieved with extracts from
papillomas induced in domestic rabbits), and a much higher
proportion of the lesions progressed, relatively rapidly, to malignancy.
The ability of CRPV to induce malignant tumors could be accelerated
if lesions were painted with croton oil (the classic tumor promoter) or
chemical carcinogens. Papillomaviruses were therefore recognized as
transmissible agents which can be used to study the induction of
benign papillomas and malignant progression.
The development of tissue culture techniques in the 1940s and
1950s enabeled investigators to study the replication of many viruses
under in vitro conditions. However, full replication of papilloma-
viruses in vitro has still not been achieved, probably because standard
tissue-culture techniques do not adequately mimic the normal
keratinocyte differentiation program, which appears to be required
for the synthesis of progeny virus particles. Furthermore, the species
specific nature of papillomaviruses, as documented in the JID [97,98],
prevented animal studies of HPV. The recognition of the difficulties
encountered with efforts toward propagating papillomaviruses in vitro
coincided with the discovery of polyoma and 3V40 viruses, which
could undergo a full replication in tissue culture, induce cellular
transformation in vitro, and induce tumors in vivo. The ease with
which these two viruses could be studied, combined with the
structural resemblance of their particles to those of papillomaviruses,
resulted in polyoma and SV40 being the subject of many studies
during the 1960s and 1970s, with few investigators continuing to work
on papillomaviruses.
The 1970s and 1980s have witnessed the re-emergence of
papillomaviruses as worthy agents to study. Advances in molecular
biology techniques, which have at least partially circumvented the
disadvantages inherent in the continuing inability to propagate these
viruses in culture, have contributed enormously to the renaissance in
papillomavirus studies. The molecular cloning of papillomavirus
genomes has in particular provided investigators with virtually
limitless quantites of high-quality virus specific reagents. Progress
has been made in three broad areas of papillomavirus research: virus
typing, the conditions associated with papillomavirus infection, and
viral pathogenesis.
Molecular analysis of papillomavirus genomes has revealed that
there are many different viral genotypes, although they share a similar
genetic organization and virion structure (reviewed in reference 99).
This diversity of virus genotypes has been studied most intensively
among the HPVs. Whereas 15 years ago it was not clear if more than
one virus was responsible for virus induced papillomas, more than 50
different HPV genotypes have now been identified. Some of these HPV
types were first described in the JID [100,101]. The vast majority of
these HPV types can be assigned to one of three large groups: those
that cause non-genital skin warts in the general population, those that
induce warts primarily in patients with epidermodysplasia verrucifor-
mis [102,103], which is a rare condition characterized by widespread
chronic cutaneous HPV infection often associated with cutaneous
squamous cell carcinomas, and those that induce lesions on mucous
membranes or genital skin [104,105]. Therefore, each HPV type tends
to cause lesions in only a subset of epithelia, with host factors also
playing an important role.
The availability of molecular clones of different HPV genomes that
can be used to probe any lesion for the presence of HPV sequences
has broadened the spectrum of conditions associated with HPV
infection. Such analysis has led to the identification of HPV in lesions
that previously had not been known to be associated with HPV
infection, including bowenoid papulosis [106] and various genital
tumors, especially carcinoma of the uterine cervix [104,105]. It has
also led to the identification of HPV DNA in the malignant tumors
associated with epidermodysplasia verruciformis [102,103]. Certain
HPV types appear to have greater malignant potential than others
because malignant lesions tend to contain only a limited subset of the
various HPV genotypes.
Molecularly cloned viral genomes have also permitted the detailed
analysis of the papillomavirus sequences in lesions, characterization of
the transcribed viral RNAs, and even identification of viral proteins
through the generation of antibodies made against viral proteins
synthesized in bacteria from the cloned viral DNA or by antibodies to
synthetic peptides made against amino acid sequences predicted from
sequence analysis of the viral DNA (reviewed in references 107,108).
This analysis has shown that a distinct region of the viral genome is
selectively retained and expressed in malignant tumors, and that the
viral DNA is generally integrated in the host genome in malignant
lesions, while benign lesions usually contain only unintegrated,
complete viral DNA genomes and transcribe most of it into RNA.
Such studies suggest that this segment of the viral genome may
participate directly in the maintenance of the malignant phenotype.
The transfer of papillomavirus sequences into cultured cells has
brought the study of these viruses to the genetic level (reviewed in
references 107,108). These studies have already enabled investigators
to assign particular functions to certain papillomavirus genes and to
elucidate in part the mechanisms by which some of the encoded viral
proteins carry out these functions. The HPV genes that are most closely
associated with cellular transformation under these experimental
conditions are those that have been found to be preferentially retained
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and expressed in malignant tumors, which further suggests their
pathogenetic importance in the tumors.
It may be anticipated that future studies will help define clearly the
role of the virus and the host in tumorigenesis. The long latent period
observed for most HPV-associated malignant tumors implies that,
while viral infection may serve an essential role in these tumors,
complementary changes in the cell are also required for malignancy.
Identification of the specific genes involved in this conversion and the
mechanism by which they and specific viral genes contribute to
tumorigenesis are important unresolved questions. The role of host
defense mechanisms in persistence, regression, or progression of
benign lesions remains poorly understood. Elucidation of host factors
could provide critical insights that might ultimately provide novel
approaches for therapeutic intervention.
It may be hoped that a molecular understanding of papillomavirus-
induced tumorigenesis will lead to rational approaches to therapeutic
intervention. If therapeutic agents were developed that interfered with
the expression of viral genes or their encoded protein products, they
would be predicted to influence bengin papillomavirus-induced
lesions, as well as those malignancies in which they were expressed.
Identification of an infectious agent raises the possibility that the
conditions it induces might be prevented by successful immunopro-
phylaxis. A great deal of additional information would be required
before such a theoretical possibility might lead to a useful product.
Much more knowledge of the immunology of HPV infection would be
necessary. Furthermore, the large number of HPV types suggests that
only a multivalent vaccine could be successful. Even successful
immunization against what are currently the most-prevalent HPV
types might provide only short-term benefits, since another HPV type
might replace relatively quickly those types eliminated by a vaccine.
We would like to thank Ms Kris Myers for her assistance in the preparation of this manuscript.
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